Version	Trial status	Changes
Ist version Issue 1, 2001 Gibson 2001	The original review had 9 included studies, 4 excluded studies and 6 studies listed as ongoing.
2nd version (substantive update) Issue 2, 2002 Gibson 2002a	This update had 10 included studies, 9 excluded studies, 3 studies listed as ongoing and 1 study awaiting assessment.	Of the four newly identified studies, one was included (Stableforth 1984), one was excluded (Warnecke 1999), one listed as ongoing (Dias 2001), and the final one was placed in 'Studies awaiting assessment' (Martin 2000). Further information obtained from trialists resulted in the exclusion of four trials that had been previously listed as ongoing studies. Three of these had been set up as a multicentre study to test the Halder nail (Halder 2001) (Brownson 2001; Hems 2000; Wallace 2000), and one had been set up to compare surgical with conservative treatment (Kulkarni 2000).
3rd version (minor update) Issue 3, 2002 Gibson 2002b	As above	Note: this update included some changes to the Discussion in response to comments received from an external reviewer.
4th version (substantive update) Issue 4, 2003 Handoll 2003a	This update had 12 included studies, 11 excluded studies, and 4 studies listed as ongoing.	Of four newly identified studies, one was included (Wirbel 1999), one excluded (de Boer 2003), and two (Frostick 2003; Shah 2003) are listed as ongoing. The other newly included trial was formerly listed as an ongoing trial (Hodgson 2003a). A trial (Martin 2000), previously in 'Studies awaiting assessment', was excluded. Limited additional findings from newly identified trial reports were included for Hoellen 1997.
5th version (minor update) Issue 2, 2007 Handoll 2007	This update had 12 included studies, 12 excluded studies, 5 studies listed as ongoing and 4 pending assessment.	Six new studies were identified: one was listed as ongoing (Fjalestad 2007), one was excluded (Flannery 2006), and the other four were placed in 'Studies awaiting assessment', pending further information.
6th version (new citation update) Issue 12, 2010 Handoll 2010	This update had 16 included studies, 18 excluded studies, 11 studies listed as ongoing and 4 pending assessment.	Sixteen new studies were identified. Of these, one was included (Fialka 2008), four were excluded (Gradl 2009; Mechlenburg 2009; Wan 2005; Yang 2006), 10 were placed in ongoing trials (Brorson 2009; HURA 2020; Liverpool (renamed as ISRCTN32335957 in the next update); NCT00438633; NCT00818987; NCT00999193; NCT01086202; NCT01113411; ProCon 2010; ProFHER 2015), and one awaits assessment (Luo 2008). New reports or information resulted in the inclusion of three more trials (Agorastides 2007: former ongoing study Frostick 2003; Fjalestad 2010a: former ongoing study Fjalestad 2007; and Lefevre‐Colau 2007: formerly Lefevre‐colau 2006, a study awaiting assessment); and the exclusion of two studies (Bing 2002: former ongoing trial Sharma 2000; Dias 2001: former ongoing trial Dias 2001 and study awaiting assessment Der Tavitian 2006).
7th version (new citation update) Issue 12, 2012 Handoll 2012	This update had 23 included studies, 26 excluded studies, 14 studies listed as ongoing and 3 pending assessment.	Overall, 18 new studies were identified. Of these, seven were included (Ockert 2010; Olerud 2011a; Olerud 2011b; Smejkal 2011; Voigt 2011; Zhang 2011; Zhu 2011), four were excluded (Carbone 2012; Edelson 2008; Liao 2009; Zhang 2010), five were placed in ongoing trials (ACTRN12610000730000; HOMERUS; NCT01557413; NTR3208; TPHF), and two await assessment (Battistella 2011; 'Fjalestad (RCT proposal)'. Further information was obtained for several studies in the previous version (Handoll 2010); this included the one‐year follow‐up report of functional outcome for Fjalestad 2010a, and information resulting in the exclusion of ISRCTN32335957, a former ongoing study. Further consideration of Shah 2003, which was listed as an ongoing study, and Pullen 2007, which was awaiting classification, led to their exclusion: it is very unlikely that any further information will be obtained for these trials, including whether they started. Also excluded was Parnes 2005, another study awaiting classification in Handoll 2010; there is currently insufficient evidence to support this being a randomised trial.
8th version (new citation update) Issue 11, 2015 Handoll 2015b	This update had 31 included studies, 38 excluded studies, 21 studies listed as ongoing and 7 awaiting classification.	Overall, 32 new studies were identified. Of these, eight were included (Boons 2012; Buecking 2014; Cai 2012; Lopiz 2014; ProFHER 2015 (5 references, including 1 trial registration and trial protocol); Sebastiá‐Forcada 2014; Soliman 2013 (2 references, including 1 trial registration); Torrens 2012 (1 reference and unpublished data)); 12 were excluded (Cigni 2012; Elidrissi 2013; Erdoğan 2014; Fan 2012; IRCT2013052313435N1; Maniscalco 2014a (2 references); Martetschlager 2012; NCT00384852; NCT01532076; NCT02122315; NTR2186; Zuckerman 2012); eight were placed in ongoing trials (NCT01524965; NCT01847508; NCT01984112; NCT02075476; NTR3895; ROTATE 2019 (2 references, including 1 trial registration); SHeRPA; Torrens 2015 2015a); and four await classification (Liu 2011 (2 papers); NCT02052206; Wang 2013; Zhu 2014). Further information was obtained for several studies in the previous version (Handoll 2012); this included the two‐year follow‐up report (Fjalestad 2014a) of functional outcome for Fjalestad 2010a, and an additional article (Ockert 2014), which reported on 48 additional participants for Ockert 2010. A trial registration document and published protocol (Fjalestad 2014b) were found for a newly designated ongoing trial (DELPHI), previously 'Fjalestad (RCT proposal)', in studies awaiting classification. Published protocols were also found for two ongoing trials (HOMERUS (Verbeek 2012); TPHF (Launonen 2012)). Additional information from updated trial registration documentation was added in for seven ongoing trials (HURA; NCT00438633; NCT00818987; NCT00999193; NCT01113411; NCT01557413; TPHF). Additional information was also available for Brorson 2009, which was moved from ongoing to studies awaiting classification.
9th version (new citation update) Issue 5, 2022	This update had 47 included studies, 77 excluded studies, 30 studies listed as ongoing and 16 awaiting classification.	Overall, 73 new studies (90 references) were identified. Of these: 10 newly included studies (18 references) were entirely new to the review: Biermann 2020 (2 references including a trial registration); Carbone 2017; Helfen 2020 (3 references including a trial registration and protocol); Jonsson 2020 (2 references including a trial registration); Lopiz 2019; Plath 2019 (2 references including a trial registration); Sohn 2017; Tousignant 2020 (3 references including a trial registration and protocol); Zhang 2019; and Ziegler 2019 (2 references including a trial registration); 33 studies (35 references) were excluded; 7 studies awaiting classification (7 references for full articles) are new to this version of the review (Baring 2017; Chen 2016; Chengjin 2017; Liu 2014; Paladini 2019; Peng 2017; Zhang 2016); 23 new ongoing studies (30 references). With the exception of Hakim 2018, which was reported in a conference abstract only, these trials were represented by trial registrations. Protocols were additionally available for Howard 2018, Launonen 2019, Nerz 2017, ReShAPE and Wu 2016 (2 protocols). An unpublished abstract was made available for NCT03217344. Further references (46 references) were obtained for 24 studies: 11 references were obtained for four already included studies: these comprised a trial registration document for Agorastides 2007; a conference abstract for Hodgson 2003a; eight reports including a long term follow‐up report for ProFHER 2015; and a commentary on Sebastiá‐Forcada 2014; 3 references were obtained for 1 study out of the 38 already excluded studies. This study was renamed from NCT02122315 to Arias‐Buria 2015. One previously excluded study, a commentary by Zuckerman 2012 on Olerud 2011b, was transferred to the latter and deleted from the excluded studies list; 31 references were obtained for 18 of the 21 previous ongoing studies. Of these: 17 references for six previously ongoing trials resulted in their move to included studies: DelPhi 2020 (formerly Delphi; 2 extra references); Gracitelli 2016 (formerly NCT01984112; 2 new references); Hengg 2019 (formerly NCT01847508; 3 new references); HURA 2020 (formerly HURA, 6 new references); Launonen 2019a (formerly one of the studies in TPHF; 3 new references); and Ring 2019 (formerly NCT00438633; 1 new reference); 8 references, all updates of trial registration documentation, were obtained for the seven trials that remained ongoing (NCT00999193; NCT01524965; NCT01557413; NCT02075476; NTR3859 (was NTR4019); SHeRPA; TPHF (second study)). A conference abstract was found for NCT01557413. 3 references were obtained for three trials that were transferred to studies awaiting classification: NCT01113411 (no new reference); NTR3208 (revised trial registration for new trial number NTR3060); ProCon 2010 (1 conference abstract and revised trial registration for new trial number NTR1923 was 2040); 3 references were obtained for six trials that were excluded: ACTRN12610000730000 (no new reference); HOMERUS (revised trial registration for new trial number NTR2354, was 2461); NCT00818987 (no new reference); NCT01086202 (updated trial registration); ROTATE 2019 (updated trial registration); Torrens 2015 (no new reference). 1 new reference was obtained for 1 of the 7 studies previous awaiting classification. This resulted in the exclusion of NCT02052206. We obtained further information, data or both from the trial contacts of three newly included studies (Jonsson 2020; Plath 2019; Tousignant 2020), three now excluded studies (HOMERUS; NCT03017105; Torrens 2015); one study awaiting classification (Brorson 2009), and two ongoing studies (NCT03217344; NTR3859).